N/A N=14 IL-17 Neutrophils in CF Lung Inflammation
Cystic Fibrosis
Primary: Change in Sputum IL-17 Neutrophils — 55; 4 % of neutrophils positive for IL-17
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
Phase 3 N=114 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
N/A N=10 Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
N/A N=7 Evaluation of the Spectra Optia PMN Cell Collection Procedure
Granulocyte/ Polymorphonuclear Cells
Primary: Granulocyte/PMN Cell Collection Efficiency — 54.7; 52.4; 41.9; 44.7 percent cells processed
N/A N=100 Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)
COPD · Emphysema · Chronic Bronchitis
Primary: Effective Concentration (EC 50) of GRO Alpha — 1.5; 0.9; 0.6 ng/ml — p=0.05
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
N/A N=17 Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
Phase 2 N=8 Efficacy and Safety of Filgrastim in Alzheimer's Disease
Alzheimer's Disease
Primary: Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL ) — 22.25; 22.25; 20.5; 17.75 units on a scale
Phase 1 N=5 Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069
Asthma
Primary: Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies — -1.21 Units on a scale
N/A N=59 Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
N/A N=15 Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
Healthy
Primary: Arthrex Angel System for PRP Concentration — 61.73; 60.86 CD45+ cells/uL
Phase 4 N=206 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants
Phase 2 N=84 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Lymphoma
Primary: CD34+ Cells/kg in Blood Stem Cells — 7.5; 10.34 CD34+ cells/kg
Phase 2 N=7 Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Primary: Percent Change of Active Blisters and in Total Blister/Erosion Counts — -29.6 percent change — p=0.82
N/A N=14 Release of Nociceptin From Granulocytes in Sepsis
Sepsis · Septic Shock · Sepsis Syndrome
Primary: Proportion of Responsive Biosensor Cells Responding to Granulocyte Addition in the Presence and Absence of NOP Antagonist — 34.25907426; 5.882352941; 44.17193917…
Phase 4 N=8 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Phase 2 N=15 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
Chronic Granulomatous Disease
Primary: Percentage of Participants With Engraftment — 100 percentage of participants
Phase 4 N=23 GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
Pediatric Sepsis-induced MODS
Primary: Number of Subjects With Restoration of the TNF-alpha Response — 10; 8 Participants
Phase 2 N=22 AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Multiple Myeloma · Lymphoma, Non-Hodgkin
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 8; 12; 4 participants
Phase 2 N=32 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
Mycobacterium Infections, Nontuberculous
Primary: Number of Participants With Sputum Culture Conversion to Negative — 2; 3 Participants
Phase 2 N=40 Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants
Phase 2 N=138 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment — 28.6; 29.3; 32.0 mmHg — p=0.1688
N/A N=56 Macrophage Phagocytosis in COPD
Chronic Obstructive Pulmonary Disease · Emphysema · Chronic Bronchitis
Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05
Phase 2 N=6 Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant — 3 participants
Phase 2 N=49 Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 23; 26; 49; 8 participants
Phase 2 N=8 AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Healthy
Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected